J

Johnson & Johnson

Makes prescription drugs and medical devices

Professional, Program Lead, Penetration Testing Services - Penetration Testing Services

Full-TimePosted on 10/19/2026Deadline 10/27/26
$94k - $151.8k+ Long-term incentive program
Senior
Bachelor's
West Chester, PA, USA+4 moreMore locations: New Brunswick, NJ, USA | Raynham, MA, USA | Warsaw, IN, USA | Palm Beach Gardens, FL, USA
HybridHybrid work at one of the listed locations; up to 10% domestic and international travel expected.
CybersecurityOffensive Security & Testing

About the job

Requirements
  • A bachelor's degree in Computer Science, Cybersecurity, Software Engineering, Electrical Engineering, Biomedical Engineering, Information Systems, or a related technical discipline.
  • A minimum of 6 years of progressive experience in penetration testing, offensive security, red teaming, or application security assessment.
  • Demonstrated experience leading or managing a penetration testing program, including methodology definition, scoping standards, and vendor oversight.
  • Hands-on proficiency across multiple domains: web application, API, mobile, network, wireless, and cloud penetration testing.
  • Working knowledge of common testing tools and frameworks including Burp Suite, Metasploit, Nmap, Wireshark, Ghidra or IDA, and Kali, plus scripting proficiency in Python, Bash, or PowerShell.
  • Strong understanding of vulnerability classes and taxonomies such as the OWASP Top 10 and CWE, and risk scoring methodologies such as CVSS.
  • Experience embedding security testing into a software development lifecycle and driving remediation with engineering teams through verified closure.
  • Ability to translate technical exploitation details into business and patient safety risk for non-technical audiences.
  • English proficiency is required.
  • OSCP, OSCE, GPEN, GWAPT, or GXPN certification is required or must be in progress.
Responsibilities
  • Own the end-to-end penetration testing services program for products and connected platforms, including the annual testing roadmap, prioritization model, and capacity planning across internal and external resources.
  • Define and maintain the penetration testing methodology, scoping standards, rules of engagement, and reporting templates aligned with OWASP, PTES, NIST SP 800-115, and MITRE ATT&CK.
  • Embed security testing gates into the product development lifecycle, ensuring Secure by Design verification occurs at defined design, integration, and pre-release milestones.
  • Execute and oversee hands-on assessments across medical devices, embedded firmware, wireless protocols, mobile applications, web applications, APIs, and cloud infrastructure.
  • Manage third-party penetration testing vendors, including scoping, statement of work development, quality review of deliverables, and performance management against service-level agreements.
  • Triage and validate findings, assess exploitability, and evaluate patient safety and clinical impact in partnership with Product Security, Quality, and Regulatory stakeholders.
  • Drive remediation with Research and Development and engineering teams, track findings through retest and verified closure, and escalate overdue or elevated risks through governance channels.
  • Conduct threat modeling and attack surface analysis to inform test scoping and identify high-value targets before engagements.
  • Produce testing evidence for FDA premarket submissions, EU MDR technical files, and hospital security assessments to support regulatory and customer requirements.
  • Contribute penetration testing results and residual risk analysis to product security risk files aligned with AAMI TIR57 and ISO 14971.
  • Build and report program metrics, including portfolio test coverage, finding severity distribution, remediation aging, and retest pass rates, to leadership and product stakeholders.
  • Research emerging attack techniques, medical device vulnerabilities, and tools; continuously evolve the testing capability and develop custom tools and exploits as needed.
  • Assess testing implications of platform migrations, supplier changes, and separation or carve-out activity affecting the product portfolio and supporting infrastructure.
  • Deliver technical enablement and secure development training to engineering teams, using real findings to strengthen security ownership and cyber culture.
Desired Qualifications
  • An advanced degree or specialized cybersecurity education.
  • MedTech or medical device experience; familiarity with FDA premarket and postmarket cybersecurity guidance, EU MDR, IEC 62304, ISO 14971, and AAMI TIR57.
  • Embedded systems and firmware security experience, including hardware interfaces such as JTAG and UART, secure boot, and reverse engineering.
  • Experience testing wireless and IoMT protocols, including Bluetooth/BLE, Zigbee, RF, and proprietary protocols.
  • Experience supporting product security testing within a divestiture, carve-out, or standalone entity stand-up.
  • Cloud penetration testing experience in AWS and/or Azure environments.
  • Exposure to coordinated vulnerability disclosure programs and researcher engagement.
  • Experience applying Generative AI or LLM-enabled tooling to accelerate reconnaissance, code review, and reporting workflows.
  • Experience integrating automated security testing into DevSecOps and CI/CD pipelines.
  • OSWE, GRTP, CRTO, or CISSP certification.
  • Up to 10% domestic and international travel is expected for lab-based device testing and site engagements.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.